Skip to main content
. Author manuscript; available in PMC: 2006 Sep 1.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3188–3196. doi: 10.1167/iovs.05-0321

Table 5.

Total Glycine-Labeled Cells

P
Treatment Group Treated Eye Fellow Eye Treated vs. Control Treated vs. Fellow Fellow vs. Control
Glaucoma
 1 Month 203.2 ± 27.2 230.2 ± 43.2 0.009 0.22 0.05 6
 2 Months 278.5 ± 12.8 276.3 ± 39.8 0.48 0.9 0.47 6
 3 Months 216.5 ± 21.3 171.4 ± 29.6 0.01 0.007 0.0006 7
Transection
 1 Month 189.7 ± 25.7 216.4 ± 3.9 0.01 0.09 0.05 4
 3 Months 99.0 ± 12.9 136.5 ± 16.2 <0.0001* 0.004 0.0004* 5
Bilateral control 301.1 ± 74.8 10
*

Difference from bilateral controls significant at P < 0.0004.